Here, we show that the detection of anti-CD19 CAR T-cells with biotinylated anti-Whitlow mAbs in blood specimens of lymphoma patients treated with Brexu-cel is unaffected by the presence or absence of blinatumomab (41% versus 42%, respectively), in contrast to the CD19-based CAR detection assay (artificially 99% versus 48%, respectively) (Figure 3D). This evidence concerns the gene CD19 and lymphoma.